Introduction: Several lines of evidence suggest the contribution of cancer stem cells (CSCs) to the tumorigenicity of bladder cancer. Although CD133 and CD24 CSC biomarkers are associated with survival disadvantages in some cancers, the biological attributes of a specific tumor alters the expression of these markers and any associated phenotypic 
Introduction
Adult stem cells are rare, highly specialized subsets of cells. They possess the functional and molecular ability of embryonic stem cells and induce pluripotent stem cells to self-renew, differentiate, and regenerate adult tissues. 1 Some tumors contain cells that have maintained the self-renewal capacity of non-malignant adult stem cells but have bypassed their growth regulatory pathways. 1 These stem celllike tumor cells are also known as cancer stem cells (CSCs) or tumor initiating cells. 2 The ability of these rare undifferentiated tumorigenic cells to self-renew and differentiate into heterogeneous lineages of neoplastic cells is the explicit biological criterion responsible for tumor initiation, maintenance, dissemination, and initiation of relapse.
The heterogeneous molecular pathogenesis of bladder cancer 1 and the frequent recurrence of superficial urothelial carcinoma (UC) 2 suggest the contribution of CSCs to their tumorgenicity. 4 The escape of CSCs, which retain full capacity to restore the tumor cell bulk, from antitumor treatments may account for the contemporary failure of therapies in this type of cancer. 4 Ultimately, understanding the biological behavior of CSCs is crucial for the development of promising CSC-targeted therapies. In addition, analyzing CSCs within a residual disease is a valuable determinant for therapy efficacy rather than the gross measurement of tumor regression. 5 Surface markers are currently used to isolate and sort CSCs. Nevertheless, the lack of well-defined surface markers for distinct tumors hinders progress. 3 The CSC marker CD133 was the first to discriminate the stem cell phenotype in solid tumors. Remarkably, the current debate in the CSC field regarding its role has not prohibited its conventional recognition as a marker of stemness in a diverse set of malignancies. 6 Transplantation of CD133-expressing CSCs into immunodeficient mice generated a histologically analogous tumor mass with self-renewal potential. The biological function of CD133 has been linked to the fate determination of stem cells and, moreover, their ability to survive viability challenges. 6 Formerly recognized as a cell marker for hematopoietic cell lineages (specifically pre-B lymphocytes prior to their maturation to plasma cells), 7 CD24 is currently documented as a CSC biomarker 8 in various cancers. [7] [8] [9] Aggressive course and ominous outcome are linked to the CD24+ subset in cancer cell nests. 10 CSCs differentiate aberrantly, thus generating heterogeneous growth of tumor bulk and essentially constructing a tumor microenvironment fundamental for their selfmaintenance. 11 Experimental evidence indicates that CSCs are not exactly identical, as various subpopulations reside within a cancer mass and possess a divergent capacity for tumorigenesis. 12 Consecutively, even among histologically identical tumors, the biological characteristics of a tumor will influence the existence and phenotype of CSCs. 3 The acquisition of stem-like cell capabilities is "context-dependent". 13 For example, although earlier studies in breast cancer have shown that CD24 overexpression was associated with node spread and advanced pathologic stages, stemness capabilities were found to be associated with CD24 downregulation combined with CD44 expression (ie, CD44 + CD24 − ). 13 Similarly, in a PC1-Expl-1 cell line, Ortiz-Montero et al found that the CD44 + CD24 − , and CD44 + CD24 + phenotypes have "dramatically" different tumorigenic capacities. 13 They concluded that it seems imperative to associate the presence or absence of CD24 expression with other events responsible for tumor initiation and/or progression. 13 In keeping with the same concept, another study found that, in gall bladder carcinoma, a CD44 + CD133 + population possesses CSC-like features and may be "true" CSCs. 14, 15 Different populations of CSCs in a tumor give it a specific oncogenic phenotype signature, which has a particular stemness capacity; this, in turn, is translated into divergent tumorigenic potential. Meanwhile, both CD24 and CD133 are customarily accepted as markers of stemness in different tumors. 6 Hence, the aim of this study was to examine the combined expression of CD133 and CD24 in the same tumors and to analyze, for the first time, the phenotypes of these two specific CSC markers for histopathological stratification of urinary bladder carcinoma by immunohistochemistry.
Materials and methods

Patients and tumor samples
A total of 60 cases were retrieved from the pathology department of Ain Shams Specialized Hospital in 2012 and 2013, according to the availability of slides and blocks with adequate tumor tissue. Data relating to tumor size and clinical parameters, including patient age and gender, were extracted from pathology reports.
Hematoxylin and eosin staining method and diagnostic criteria
Sections of 4 µm in thickness were sliced from formalinfixed, paraffin-embedded blocks and stained with hematoxylin and eosin. The slides were examined to determine histological tumor type, grade, stage, and evidence of schistosomiasis infection within the tumor or adjacent nontumor tissue. To avoid data fragmentation, cases were segregated as UCs and non-UCs. Pathological grade was defined according to the latest World Health Organization (WHO) criteria, 2016. 16 Tumor stage was determined according to the American Joint Committee on Cancer (AJCC) TNM nodal staging system 17 depending on the degree of infiltration of the bladder wall layer and extension into the perivesical fat and the adjacent organs. Accordingly, pTa tumors are defined as tumors that do not invade the lamina propria, pT1 tumors grow under the basement membrane into the lamina propria, pT2 tumors invade the muscularis propria, pT3 tumors invade perivesical tissue, and pT4 tumors show direct invasion into the prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall or abdominal wall. The WHO 2016 system categorizes non-muscle invasive UCs (ie, pTa and pT1) as either low grade or high grade. If different grades are detected in the same lesion, the tumor is graded according to the highest grade noted. Non-invasive papillary low grade UC is characterized by orderly arranged papillae with mild cytological atypia and rare mitosis. In contrast, non-invasive papillary high grade UCs are characterized by a disorderly appearance due to both cytological atypia and architectural disorganization. However, all muscle invasive UCs (pT2-4) are classified as high grade tumors. Non-UC was categorized according to the grade of differentiation into low grade (well/moderately differentiated) and high grade (poorly differentiated).
Immunohistochemical staining
Primary antibodies targeting CD133 (rabbit, polyclonal, diluted 1/100, CP 348, A, B, C BioCare Medical) and CD24 (mouse, monoclonal, diluted 1/100, SN3b, BioCare Medical) were used.
Briefly, sections were deparaffinized, dehydrated, and immersed in methanol. Slides were microwaved for 10 minutes in citrate buffer (pH=6) for antigen retrieval and incubated with primary antibodies overnight at room temperature. Bound antibody was detected by avidin-biotin using diaminobenzidine as the chromogen, followed by nuclear counterstaining with hematoxylin. In each run, positive and negative controls were used throughout. Normal kidney tissues and breast carcinoma tissues were used as the appropriate positive controls for CD133 and CD24 antibodies, respectively.
Evaluation of CD133 and CD24
Analysis was independently performed using computerized Image Analysing Software (Special SIS starter, version 3.2, Olympus Corporation, Tokyo, Japan) connected to an Olympus microscope (model BX51) by three pathologists blinded to the patients' clinical and pathological information.
Cells showing a membranous and/or cytoplasmic staining pattern were considered positive. The percentage of positively stained cells, with unequivocal strong to moderate staining intensities, was determined in ten mediumpower fields. Tumor cells were evaluated in the most prominent staining areas. 
Compliance with ethical standards
This research complied with all the relevant national regulations and institutional policies. It is in accordance with the tenets of the Helsinki Declaration. The study was approved by the Research Ethics Committee, Faculty of Medicine, Ain Shams University (FMASU 870/2010). Patient data confidentiality and anonymity were maintained. This is a retrospective study that used paraffin blocks retrieved from the archives of the Department of Pathology and followed strict regulations that guarantee the patients' rights and welfare. Accordingly, this research carries no risk of harm to patients and will not affect their rights or welfare. Hence, the Institutional Review Board waived patient consent.
Results
Clinicopathological characteristics
The patients' mean age (± SD) was 57 (±7.43) years with a male to female ratio of 4:1. Histopathological examination revealed 50 UC and ten non-UC carcinoma (squamous cell carcinoma (n=8) and adenocarcinoma (n=2)) cases. Thirty-seven percent of the tumors were low grade, and 63% were high grade. Twentyseven percent of the tumors were non-muscle invasive, and 73% were muscle invasive tumors. Seventeen percent of the tumors were associated with schistosomiasis. Lymphovascular invasion (LVI) and perineural invasion were observed in 10% and 7% of the patients, respectively.
Nodal spread and distant metastasis occurred in 12% and 8% of the patients, respectively. The patients' clinicopathological characteristics are shown in Table 1 .
Immunohistochemical expression and cellular distribution of CD133 and CD24
CD133 was expressed in carcinoma cells in 22 (36.67%) out of 60 cases. CD133 protein expression was categorized as low (<50%) or high (≥50%) in 12 and ten cases, respectively. CD24 was expressed by carcinoma cells in 17 cases (28.3%), and the staining pattern was categorized as low (<10%) or high (≥10%) in seven and ten cases, respectively. Figure 2 ). Similarly, in UC, the prevalence of CD133 and CD24 tumor cells increased in non-papillary high grade US (n=16/18, %, and 13/13, 100%, respectively) compared to papillary low grade UC (p=0.016 and 0.002, respectively) ( Figures 1 and 2 ). Advanced stage was significantly associated with CD133 + and CD24 + tumor cells (p=0.001 and 0.007, respectively) ( Table 2) . Although neither CD133 nor CD24 expression affected lymph node spread, only CD24 expression was weakly correlated with LVI (p=0.04) (Table 2, Figure 3 ). On the other hand, only CD133 expression was associated with distant metastasis. Five (8.3%) patients developed distant metastasis at different time intervals after complete resection, and this was strongly associated with CD133 expression in the primary tumor (n=5/5, 100%, p=0.004) ( Table 2 ). The patient's age, gender, histological tumor type, associated bilharzia infestation, and perineural invasion did not influence the presence of either CD133 + or CD24 + tumor stem cells (Table 2) .
Association of CD133 and
Correlation between CD133 and CD24 expression
The pattern of CD133 expression showed a significant positive correlation with the pattern of CD24 expression 
Histological grade
Low (1& 2) (n=22)
3 (25) 1 (10) 18 ( 1 (10) 6 (13.9)
Lymph node metastasis Present (n=7) 
Discussion
Early research has indicated that CSCs are a rare population. 20 It is currently unknown whether all cancers contain subpopulations of CSCs. 20 Herein, CD133 and CD24 were identified in 44% and 28.3% of the tumor tissues tested, respectively. Accumulating evidence has confirmed that a stem cell hierarchy is not applicable to all tumors. Tumor type and cell of origin together with the oncogenic events driving "stemness" may indeed determine the absolute frequency of CSCs. 21 CSCs, as hypothesized, originate from normal stem cells/progenitor cells, 22 whereas oncogenic mutations ensure their uncontrolled proliferation. 23 27 specifically in tumors that have invaded the muscle layer. 10 Our results suggest a potent tumorigenic potential of the CD133 + subset and are consistent with the aggressive in vitro proliferation capacity of these cells. 26 Another study that found a nonsignificant correlation between CD133 and clinicopathological parameters is seemingly conflicting, 19 but the diverse study methodology may conceptualize the contradictions. In a tissue microarray, the sampled small cores may not represent the whole tumor, particularly with the complexity of clonal evolution driving the "stemness" of malignancy. 3, 21 CD24 is another putative marker to isolate CSCs from solid tumors. 8 Similar to CD133 + CSCs, CD24 + CSCs were frequent in high grade muscle invasive carcinomas with advanced stage. A meta-analysis of the studies on the association between CD24 expression and prognostic factors in diverse carcinomas published in 1990-2009 determined that CD24 is a significant marker of malignancy and poor prognosis in numerous cancers. 7 Specifically, CD24 may endorse cancer development and progression in ovary, breast, and urinary bladder. Overall, CD24 significantly correlated with lymph node metastasis Overall, CD133 and CD24 were expressed in tumor cells of bladder carcinoma and correlated with determinants of tumor behavior. The preferential expression of (n=10) 1 (10) 3 (25) 32 Such plasticity creates a dynamic equilibrium that may be shifted in one direction or another to generate unstable, epigenetic, or intrinsic genetic differences between tumorigenic and nontumorigenic cells within the same tumor. 4, 33, 34 Although the search for CSCs can pull up different markers, 20 an optimal combination of markers has not yet been established to ascertain CSCs in relation to invasion, metastasis, and therapeutic resistance in a certain tumor. 8 The genetic heterogeneity and different mutational patterns of bladder carcinoma are likely adjoined by the heterogeneous complexity of CSCs, which bolsters the prognostic significance of different CSC phenotypes. 24 While injection of a few breast CSCs with the ESA + / CD44 + /CD24 low-neg phenotype into NOD/SCID mice reinitiated the original tumor, 10,000 cells with alternate phenotypes failed. 24, 34 Several phenotypes have been proposed in other cancers (eg, CD44 + /CD24 low-neg phenotype in breast cancer) but not in urinary bladder carcinoma. For the first time, the present study addressed the clinical characteristics of different CD133/CD24
phenotypes. In summary, our comparative analysis may provide initial insights into the potential impact of each marker. frequently associated with advanced tumor stages. This finding ultimately supports our prior hypothesis associating the CD133 + subset with more aggressive behavior. It is hypothesized that CD133 has an inherent effect on the attachment of stem cells to their niche 35, 36 and an ability to fine-tune tumor biology by controlling diverse cellular processes, eg, glucose and transferrin uptake, autophagy, membrane-membrane interaction, and matrix metalloproteinase functions. 24 Accordingly, several CD133 + solid tumors in other systems have poor clinical outcomes and shorter overall survival.
6
CD24 is a ligand of an adhesion receptor present on activated endothelial cells and platelets. 10 Accordingly, CD24 + tumor cells theoretically can form tumor thrombi and advance toward metastasis. 10 Herein, CD24 did not correlate with lymph node metastasis and showed a borderline correlation with LVI. Studies that exist lack a rationale for why there is a nonsignificant correlation between CD24 and either LVI or lymph node metastasis. 10 However, following a brief review of the existing evidence, the intriguing occurrence of LVI and lymph node spread in tumors exhibiting the CD133 This observation may strengthen the causal inference describing CD24 as a "lynchpin" of metastatic progression and colonization rather than just a mediator of endothelial cell adhesion. 41 The similar association of the CD133 27 and are thus linked to radioresistance due to amplified DNA repair following irradiation.
26
"Cancer stem cells are hard to identify because a practical operating definition has never been achieved", says Scott Kern. 20 Studies analyzing surface markers to isolate CSCs, such as CD133 and CD24, are contradictory even among the same type of carcinomas. 7 We believe that the diversity in evaluating the immunoexpression of these surface markers created these controversies. Although scientists disagree over how a small and distinct population of cells can enhance tumors, they tend to agree that the assays to discern such cells "can be lousy". 20 Various cut-off levels of the same marker have been proposed among multiple studies. Moreover, some studies have used the cut-off to define expression positivity, while other studies used the same cut-off value to segregate cases into low vs high expression. Moreover, in some reports, the immunoreactivity was described as the percentage of tumor cells with positive expression, while other studies described only the staining intensity. Even research that evaluated the percentage of area stained at each intensity level sub-classified the study cohorts differently. The isolation of CSCs is still an enduring ambiguity necessitating a valid method for evaluating their immunoexpression. These variations yielded distinct results vis-à-vis the relevance of a single marker to clinical disease in the respective malignancies. Standardization of the analytic methodology for various surface markers will undoubtedly enhance the prospective characterization and isolation of CSCs in human malignancies. The Cancer Genome Atlas (TCGA) consortium and individual research groups have recently proposed several genome-based molecular classifications of UC (ie, University of North Carolina, MD Anderson Cancer Center, TCGA, Lund University, Baylor College Of Medicine, the CIT Classification, and others). 46 However, these classifications still have several limitations that prevent their current integration into clinical practice. 
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